Alfuzosin, an α1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: Once daily versus 3 times daily dosing in healthy subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 40, Issue 7, 2002, Pages 289-294

  Ahtoy, P ^a   Chretien P ^a   Dupain, T ^a   Rauch, C ^a   Rouchouse, A ^a   Delfolie, A ^a  

^a CéMax 3 ^*  (France)

Author keywords

Alfuzosin; OD formulation; Pharmacokinetics; TID formulation

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; QUINAZOLINE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PATENT; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SPECTROFLUOROMETRY; STEADY STATE; SUSTAINED RELEASE FORMULATION; TABLET; ANALYSIS OF VARIANCE; BIOAVAILABILITY; BLOOD; COMPARATIVE STUDY; DRUG ANTAGONISM; MIDDLE AGED;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; QUINAZOLINES; RECEPTORS, ADRENERGIC, ALPHA-1;

EID: 0035988939     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp40289     Document Type: Article

References (17)

1. Uroselectivity
2. The development of human benign prostatic hyperplasia with age
3. Clinical uroselectivity: Evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction
4. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia
5. Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia
6. Alfuzosin: A comparison of the steady state pharmacokinetics of two dosages in middle-aged and elderly healthy male volunteers
7. Sample size determination for bioequivalence assessment by means of confidence intervals
8. α-blockade in the treatment of symptomatic benign prostatic hyperplasia
9. Alfuzosin for the treatment of benign prostatic hypertrophy
10. 1-adrenoceptor antagonist in the lower urinary tract
11. Safety profile of 3-month therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy
12. Relationship between the effects of alfuzosin on rat urethral and blood pressures and its tissue concentrations
13. Pharmacokinetic and metabolic profiles of alfuzosin
14. Pharmacokinetics of alfuzosin after single oral administration to healthy volunteers, of three different doses
15. Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin
16. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia
17. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and the therapeutic potential in benign prostatic hyperplasia